These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11462019)

  • 21. Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251.
    Kent KA; Kitchin P; Mills KH; Page M; Taffs F; Corcoran T; Silvera P; Flanagan B; Powell C; Rose J
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):189-94. PubMed ID: 8198871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.
    Santra S; Tomaras GD; Warrier R; Nicely NI; Liao HX; Pollara J; Liu P; Alam SM; Zhang R; Cocklin SL; Shen X; Duffy R; Xia SM; Schutte RJ; Pemble Iv CW; Dennison SM; Li H; Chao A; Vidnovic K; Evans A; Klein K; Kumar A; Robinson J; Landucci G; Forthal DN; Montefiori DC; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; Michael NL; Kim JH; Soderberg KA; Giorgi EE; Blair L; Korber BT; Moog C; Shattock RJ; Letvin NL; Schmitz JE; Moody MA; Gao F; Ferrari G; Shaw GM; Haynes BF
    PLoS Pathog; 2015 Aug; 11(8):e1005042. PubMed ID: 26237403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic HIV-2 infection protects against total CD4+ cell depletion and rapid disease progression induced by SHIV89.6p challenge.
    Otten RA; Adams DR; Kim CN; Pullium JK; Sawyer T; Jackson E; Folks TM; Butera S
    AIDS; 2004 May; 18(8):1127-35. PubMed ID: 15166528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Better protective effects in rhesus macaques by combining systemic and mucosal application of a dual component vector vaccine after rectal SHIV89.6P challenge compared to systemic vaccination alone.
    Stolte-Leeb N; Bieler K; Kostler J; Heeney J; Haaft PT; Suh YS; Hunsmann G; Stahl-Hennig C; Wagner R
    Viral Immunol; 2008 Jun; 21(2):235-46. PubMed ID: 18476770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection.
    Van Rompay KK; Berardi CJ; Dillard-Telm S; Tarara RP; Canfield DR; Valverde CR; Montefiori DC; Cole KS; Montelaro RC; Miller CJ; Marthas ML
    J Infect Dis; 1998 May; 177(5):1247-59. PubMed ID: 9593009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simian immunodeficiency virus SIVmac239 infection and simian human immunodeficiency virus SHIV89.6P infection result in progression to AIDS in cynomolgus macaques of Asian origin.
    Okamura T; Tsujimura Y; Soma S; Takahashi I; Matsuo K; Yasutomi Y
    J Gen Virol; 2016 Dec; 97(12):3413-3426. PubMed ID: 27902330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
    J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.
    Mascola JR
    Vaccine; 2002 May; 20(15):1922-5. PubMed ID: 11983246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope.
    Quesada-Rolander M; Mäkitalo B; Thorstensson R; Zhang YJ; Castaños-Velez E; Biberfeld G; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):993-9. PubMed ID: 8827215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.
    Reimann KA; Watson A; Dailey PJ; Lin W; Lord CI; Steenbeke TD; Parker RA; Axthelm MK; Karlsson GB
    Virology; 1999 Mar; 256(1):15-21. PubMed ID: 10087222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
    McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
    J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
    Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
    J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of apoptosis induction in both peripheral lymph nodes and thymus in progressive loss of CD4+ cells in SHIV-infected macaques.
    Iida T; Ichimura H; Shimada T; Ibuki K; Ui M; Tamaru K; Kuwata T; Yonehara S; Imanishi J; Hayami M
    AIDS Res Hum Retroviruses; 2000 Jan; 16(1):9-18. PubMed ID: 10628812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.
    Gautam R; Nishimura Y; Gaughan N; Gazumyan A; Schoofs T; Buckler-White A; Seaman MS; Swihart BJ; Follmann DA; Nussenzweig MC; Martin MA
    Nat Med; 2018 May; 24(5):610-616. PubMed ID: 29662199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.